Loading clinical trials...
Loading clinical trials...
A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Who Have Chronic HCV-1/HIV-1 Co-Infection and Are Treatment-Naïve for Hepatitis C
The purpose of this study is to determine whether the combination of telaprevir, peginterferon alfa-2a, and ribavirin is safe and effective in treating hepatitis C virus (HCV) infection in subjects who are infected with both HCV and human immunodeficiency virus (HIV).
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
Beverly Hills, California, United States
San Diego, California, United States
San Francisco, California, United States
Miami, Florida, United States
Orlando, Florida, United States
Chicago, Illinois, United States
Baltimore, Maryland, United States
Boston, Massachusetts, United States
New York, New York, United States
Cincinnati, Ohio, United States
Start Date
October 1, 2009
Primary Completion Date
March 1, 2012
Last Updated
October 10, 2013
62
ACTUAL participants
telaprevir or matching placebo
DRUG
telaprevir or matching placebo
DRUG
peginterferon alfa-2a
BIOLOGICAL
ribavirin (fixed dose)
DRUG
ribavirin (weight-based dose)
DRUG
Lead Sponsor
Vertex Pharmaceuticals Incorporated
Collaborators
NCT04142047
NCT06694805
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07428330